Cepheid Stock Soars on News of New York Anthrax Case | GenomeWeb

NEW YORK, Oct. 12 – Shares in Cepheid skyrocketed nearly 50 percent during mid-day trading on Friday after reports surfaced that an employee of NBC in New York was diagnosed with anthrax.

As of 2:00 p.m. EST, shares in the company, which makes and sells technology that performs genetic testing, were trading up more than 48 percent at $8.10 on the Nasdaq but eased a bit one hour later.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.